Role of the gut microbiota–bile acid axis in liver fibrosis, based on microbiomics and targeted metabolomics

Effective diagnoses and treatments for liver fibrosis (LF) are lacking. The gut microbiota (GM)–bile acid (BA) axis is crucial in LF development and may be a target for delaying or reversing LF. We combined fecal microbiomics and BA-targeted metabolomics to characterize the GM-BA axis in rats with LF and used fecal microbiota transplantation (FMT) and probiotics to regulate the GM-BA axis to investigate the role of the GM-BA axis in LF and its related mechanisms.